Records containing: PDAC - Pancreatic Ductal Adenocarcinoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-03-24Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR 1 / BIORESOURCE)
-
CLINICAL_TRIALS study record update · 2026-03-24Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)
-
CLINICAL_TRIALS study record update · 2026-03-23A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers
-
CLINICAL_TRIALS study record update · 2026-03-18A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6103, a Novel FAP-activated Exatecan Administered Intravenously in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-03-13An Exosome-based Liquid Biopsy Signature for Preoperative Identification of Occult Liver Metastasis in Patients With Pancreatic Ductal Adenocarcinoma
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-03-10A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
-
CLINICAL_TRIALS study record update · 2026-03-05A Phase 1 Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-02-27A Phase I/IIa Randomized Clinical Trial to Evaluate the Efficacy of EGFR-targeted, PNU-159682-packaged Nanocells & Glycolipid-Packaged Nanocells in Combination With Gemcitabine & Nab-paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
-
CLINICAL_TRIALS study record update · 2026-02-25A Randomized Double Blind Study of Pancreatic Enzyme Replacement Therapy for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
-
CLINICAL_TRIALS study record update · 2026-01-22A Phase 2, Multicenter, Single Arm, Open Label Non-Randomized Study of [68Ga]FAPI-46 PET in Patients With Resectable or Borderline Resectable Pancreatic Ductal Carcinoma
-
CLINICAL_TRIALS study record update · 2026-01-13A Randomized, Controlled, Phase III Study of Gemcitabine and Nab-paclitaxel (GnP) Combined With Stereotactic Body Radiation Therapy (SBRT) and Serplulimab Versus GnP as First-Line Therapy in Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)
-
CLINICAL_TRIALS study record update · 2025-12-22Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA): an International Randomized Controlled Multicenter Trial
-
CLINICAL_TRIALS study record update · 2025-12-17MRI Imaging to Predict Outcomes of Treatment in PDAC Patients
-
CLINICAL_TRIALS study record update · 2025-12-12RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus Investigator's Choice of Standard of Care Therapy in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
-
CLINICAL_TRIALS study record update · 2025-09-22Pancreatic Cancer Glucose Assessment and Regulation Study
-
CLINICAL_TRIALS study record update · 2025-08-12Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
-
CLINICAL_TRIALS study record update · 2025-08-05High Efficiency of Early Detection of Synchronous Pancreatic Ductal Adenocarcinoma in Patients With Chronic Pancreatitis
-
CLINICAL_TRIALS study record update · 2025-07-01Pancreatic Cancer First-line NALIRIFOX Optimization With 5-FU Maintenance and Role of Antibiotics and Microbiota Exploration in Second-line Treatment - A Non-comparative, Randomized Phase II PANORAMIX GERCOR G-116 PRODIGE 105 Study.
-
CLINICAL_TRIALS study record update · 2025-06-06A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Intravenous Push Followed by a Continuous Infusion of Certepetide Over 4 Hours When Added to Standard of Care (SoC) Versus Two Intravenous Pushes of Certepetide When Added to SoC, Versus SoC Alone in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (FORTIFIDE)
-
CLINICAL_TRIALS study record update · 2025-06-03Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
-
CLINICAL_TRIALS study record update · 2025-04-27Multicenter, Case-Control Clinical Validation Study of a Multiplex Blood Protein Biomarker Test, IMMNOV-2, for Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in High-Risk Patients
-
CLINICAL_TRIALS study record update · 2024-12-31Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer: a Prospective, Randomized Controlled Clinical Trial
-
CLINICAL_TRIALS study record update · 2023-07-17The Safety and Tolerance of Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in Subjects With Locally Advanced and Metastatic Pancreatic Adenocarcinoma: an Open, One-Armed, Single-Center, Phase Ⅱ Study.
-
CLINICAL_TRIALS study record update · 2023-05-10Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability
-
CLINICAL_TRIALS study record update · 2023-05-06Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer